Maxim lowered the firm’s price target on Health In Tech (HIT) to $4 from $4.50 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect the company’s Q4 results as well as the dilution from the equity raise announced yesterday, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIT: